MSL DAILY PHARMA NEWS - Merck and Pfizer’s SGLT2 inhibitor STEGLATRO meets primary endpoint in VERTIS CV trial #SGLT2 #PFIZER #STEGLATRO “Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated STEGLATRO (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus placebo, added to background standard of care treatment, in more than 8,200 patients with type 2 diabetes and atherosclerotic CV disease across 531 centers in 34 countries. Overall, the primary MACE outcome was reported in 11.9% (n=653) of patients treated with STEGLATRO (5 mg and 15 mg doses), compared with 11.9% (n=327) of patients treated with placebo (HR=0.97; 95.6% CI [0.85-1.11]; p<0.001 for non-inferiority). The key secondary endpoints of superiority for ertugliflozin versus placebo were not met. “ Free webinar on “how to become an MSL” https://lnkd.in/gFYBJ2G Or click on our profile. Click below to read further, like and share it and follow us to learn more. Our MSL testimonials: Http://https://lnkd.in/eEfHu4c #MSL #FSTP #MSLcert #medicalscienceliaison https://www.instagram.com/p/CBkbzZjDFjX/?igshid=rn4rlatmac86
